胃癌患者血清sICAM-1、sVCAM-1和sFas水平的研究  

Serum Levels of Soluble ICAM-1, VCAM-1 and Fas in Patients with Gastric Cancer

作　　者：王裕发[1] 巫协宁[1] 张晓琼[1] 陈霞芳[1] 

机构地区：[1]上海市第一人民医院,200080

出　　处：《胃肠病学》1998年第4期211-213,共3页Chinese Journal of Gastroenterology

摘　　要：目的:为了解胃癌患者血清中可溶性细胞间粘附因子-1(sICAM.1)、血管间粘附因子.1(sVCAM-1)和Fas受体(sFas)的水平变化 方法:用双抗体夹心ELISA法检测了32例胃癌患者及25名正常健康人血清sICAM-1、sVCAM-1和sFas水平 结果:发现胃癌患者sICAM-1和sVCAM-1水平明显高于正常健康人(289.25±32.69ng/ml比190.44±35.92ng/ml:1430.88±421.71ng/ml比727.24±157.68ng/ml),差异显著,且与临床分期有关。而胃癌患者血清sFas水平则明显低于正常健康人(8.55±2.45ng/ml比12.33±4.02ng/ml),差异显著(P<0.01).但与临床分期无关 结论:sICAM-1 sVCAM-1在胃癌的发生发展中起着重要作用,患者血清水平的测定,对病情、病期、预后的判断及治疗效果的观察均具有重要意义 而胃癌细胞与其他大部分肿瘤细胞不同.对sFas调节作用可能并不敏感。Background Aims: To observe the changes of sICAM-1. sVCAM-1 and sFas in patients with gastric cancer Methods: The serum levels of sICAM-1. sVCAM-1 and sFas in 32 patients with gastric cancer and 25 healthy controls was measured by sandwich enzyme immunoassay. Results: The soluble ICAM-1 and VCAM-1 levels in gastric cancer were found to be significantly elevated in comparison with those of healthy subjects (289.25 ±32.69ng/ml vs 190.44 ± 35.92ng/ml: 1430.88±421.71ng/ml vs 727 24 ±157.68ng ml. respectively). The increment in serum sICAM-1 and sVCAM-1 levels correlated well with the staging of gastric cancer; The soluble Fas levels in gastric cancer were found to be significantly decreased in comparison with those of healthy subjects (8.55±2.45ng/ml vs 12.33±4.02ng/ ml) and were not correlated with the staging of disease. Conclusions: sICAM-1 and sVCAM-1 may play an important role in tumorgenesis and tumor development. The sICAM-1 and sVCAM-1 might be a marker for therapeutic effect and predicting prognosis of the disease. And the gastric cancer (which is different from most other tumor cells) may not be sensitive to the regulatory action of sFas.

关 键 词：胃癌 可溶性间粘附因子-1 血管间粘附因子-1 FAS受体 

分 类 号：R735.2[医药卫生—肿瘤]